 Immunosuppressive Agents
"Immunosuppressive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
| Descriptor ID |
D007166
|
| MeSH Number(s) |
D27.505.696.477.656
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunosuppressive Agents".
Below are MeSH descriptors whose meaning is more specific than "Immunosuppressive Agents".
This graph shows the total number of publications written about "Immunosuppressive Agents" by people in this website by year, and whether "Immunosuppressive Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1981 | 1 | 0 | 1 | | 1982 | 1 | 1 | 2 | | 1984 | 0 | 1 | 1 | | 1987 | 1 | 1 | 2 | | 1988 | 0 | 3 | 3 | | 1989 | 0 | 1 | 1 | | 1990 | 15 | 1 | 16 | | 1991 | 10 | 2 | 12 | | 1992 | 2 | 2 | 4 | | 1993 | 8 | 3 | 11 | | 1994 | 11 | 3 | 14 | | 1995 | 10 | 2 | 12 | | 1996 | 23 | 14 | 37 | | 1997 | 26 | 16 | 42 | | 1998 | 36 | 14 | 50 | | 1999 | 29 | 19 | 48 | | 2000 | 15 | 12 | 27 | | 2001 | 18 | 12 | 30 | | 2002 | 9 | 7 | 16 | | 2003 | 20 | 8 | 28 | | 2004 | 16 | 15 | 31 | | 2005 | 14 | 10 | 24 | | 2006 | 23 | 13 | 36 | | 2007 | 10 | 15 | 25 | | 2008 | 10 | 13 | 23 | | 2009 | 11 | 11 | 22 | | 2010 | 15 | 11 | 26 | | 2011 | 12 | 7 | 19 | | 2012 | 14 | 10 | 24 | | 2013 | 16 | 15 | 31 | | 2014 | 16 | 7 | 23 | | 2015 | 6 | 11 | 17 | | 2016 | 13 | 9 | 22 | | 2017 | 9 | 8 | 17 | | 2018 | 8 | 4 | 12 | | 2019 | 5 | 7 | 12 | | 2020 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunosuppressive Agents" by people in Profiles.
-
Rosen MH, Axelrad J, Hudesman D, Rubin DT, Chang S. Management of Acute Severe Ulcerative Colitis in a Pregnant Woman With COVID-19 Infection: A Case Report and Review of the Literature. Inflamm Bowel Dis. 2020 06 18; 26(7):971-973.
-
Sprague SM. Interventions for Preventing Bone Disease Following Kidney Transplantation: Is There Evidence for Specific Therapy? Am J Kidney Dis. 2020 05; 75(5):809-811.
-
Farrell RM, Johannesson L, Flyckt R, Richards EG, Testa G, Tzakis A, Falcone T. Evolving ethical issues with advances in uterus transplantation. Am J Obstet Gynecol. 2020 06; 222(6):584.e1-584.e5.
-
Lee JR, Huang J, Magruder M, Zhang LT, Gong C, Sholi AN, Albakry S, Edusei E, Muthukumar T, Lubetzky M, Dadhania DM, Taur Y, Pamer EG, Suthanthiran M. Butyrate-producing gut bacteria and viral infections in kidney transplant recipients: A pilot study. Transpl Infect Dis. 2019 Dec; 21(6):e13180.
-
Oz RS, Gluth M, Tesher MS. Pediatric Autoimmune Inner Ear Disease: A Rare, But Treatable Condition. Pediatr Ann. 2019 Oct 01; 48(10):e391-e394.
-
Weisshof R, Ollech JE, El Jurdi K, Yvellez OV, Cohen RD, Sakuraba A, Dalal S, Pekow J, Rubin DT. Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe. J Crohns Colitis. 2019 Sep 19; 13(9):1105-1110.
-
Johannesson L, Wall A, Putman JM, Zhang L, Testa G, Diaz-Garcia C. Rethinking the time interval to embryo transfer after uterus transplantation - DUETS (Dallas UtErus Transplant Study). BJOG. 2019 Oct; 126(11):1305-1309.
-
van Besien K, Artz A, Champlin RE, Guarneri D, Bishop MR, Chen J, Gergis U, Shore T, Liu H, Rondon G, Mayer SA, Srour SA, Stock W, Ciurea SO. Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. Blood Adv. 2019 06 25; 3(12):1858-1867.
-
Gergis U, van Besien K. Tocilizumab, in search for a role in acute GVHD. Leuk Lymphoma. 2019 09; 60(9):2101-2103.
-
Ju A, Josephson MA, Butt Z, Jowsey-Gregoire S, Tan J, Taylor Q, Fowler K, Dobbels F, Caskey F, Jha V, Locke J, Knoll G, Ahn C, Hanson CS, Sautenet B, Manera K, Craig JC, Howell M, Rutherford C, Tong A, Harden P, Hawley C, Holdaas H, Israni A, Jesse M, Kane B, Kanellis J, Kiberd B, Kim J, Larsen C, Leichtman A, Lentine K, Malone A, Mannon R, Oberbauer R, Patzer R, Peipert JD, Phan HA, Poggio E, Reed R, Scandling J, Tang I, Watson C, Contrares D, Contreras P, Cross D, Juodvalkis E, Koide D, Koide J, Kozarewicz A, Kozarewicz L, Kozarewicz R, Koritala A, Lisiecki E, Lipuma C, Lyman M, Mueller R, Mueller G, Noble L, Nolan N, Nolan S, Thomas J, Urbancyzk L, Zerante J, Zerante S. Establishing a Core Outcome Measure for Life Participation: A Standardized Outcomes in Nephrology-kidney Transplantation Consensus Workshop Report. Transplantation. 2019 06; 103(6):1199-1205.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|